Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tracleer Extension in PAH with Eisenmenger Physiology
NCT00367770Phase 4Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jan 2004
- Primary completion
- Dec 2005
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 11
01
Overview
Phase 4, open-label, single-arm trial of bosentan in pulmonary arterial hypertension (PAH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Change in 6-minute Walk Distance at 24 weeks, Change in Borg Dyspnea Index at 24 weeks and 1 more. Started Jan 2004; status: completed.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00367770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367770.